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The synergy of carbapenem combinations regarding Enterobacteriaceae producing
different types of carbapenemases was study through different approaches: flow
cytometry and computational analysis. Ten well characterized Enterobacteriaceae (KPC,
verona integron-encoded metallo-β-lactamases –VIM and OXA-48-like enzymes) were
selected for the study. The cells were incubated with a combination of ertapenem with
imipenem, meropenem, or doripenem and killing kinetic curves performed with and
without reinforcements of the drugs. A cephalosporin was also used in combination
with ertapenem. A flow cytometric assay with DiBAC4-(3), a membrane potential dye,
was developed in order to evaluate the cellular lesion after 2 h incubation. A chemical
computational study was performed to understand the affinity of the different drugs to
the different types of enzymes. Flow cytometric analysis and time-kill assays showed a
synergic effect against KPC and OXA-48 producing-bacteria with all combinations; only
ertapenem with imipenem was synergic against VIM producing-bacteria. A bactericidal
effect was observed in OXA-48-like enzymes. Ceftazidime plus ertapenem was
synergic against ESBL-negative KPC producing-bacteria. Ertapenem had the highest
affinity for those enzymes according to chemical computational study. The synergic
effect between ertapenem and others carbapenems against different carbapenemase-
producing bacteria, representing a therapeutic choice, was described for the first time.
Easier and faster laboratorial methods for carbapenemase characterization are urgently
needed. The design of an ertapenem derivative with similar affinity to carbapenemases
but exhibiting more stable bonds was demonstrated as highly desirable.
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INTRODUCTION
Worldwide carbapenem resistance is growing leading to
increased morbidity and mortality caused by multidrug resistant
pathogens (MDR) and costs due to longer hospital stay (Patel and
Bonomo, 2011; Nordmann et al., 2012; Tzouvelekis et al., 2012).
Carbapenemases are enzymes that destroy almost all β-lactams.
Infections caused by these bacteria are difficult to treat as only few
antibiotics (including colistin, tigecycline, and aminoglycosides)
may remain effective, and resistance to these compounds has
also recently emerged in Enterobacteriaceae. Treatment with
a single effective antibiotic is associated with an unacceptably
high mortality rate, and combination regimens should be the
rule to obtain a clear survival benefit (Tzouvelekis et al., 2014).
Minimal inhibitory concentrations (MIC) >0.125 mg/L for
either meropenem or ertapenem and >1 mg/mL for imipenem,
require screening of carbapenemase production (EUCAST,
2013). Anderson et al. (2007) found that ertapenem susceptibility
is the most sensitive indicator of KPC activity. We speculate
that the ertapenem is the less effective among carbapenems
because the affinity of ertapenem for carbapenemases is also
the highest. Therefore, we tested the hypothesis that ertapenem
could be used to maintain carbapenemases occupied allowing
the other carbapenems to remain intact. Similar strategies
were used regarding the association between clavulanic acid
and β-lactamics drugs as it was described as subtract of
β-lactamases (Neu and Fu, 1978). Pioneer studies performed
using animal models of infections or experimental treatments of
patients have suggested the use of carbapenem combinations for
treating infections, however, they are limited (Wiskirchen et al.,
2013a,b, 2014a) encompasses few enzymes and deserved further
explanation.
Thus, we studied the association between ertapenem and
the other three carbapenems: imipenem, meropenem, and
doripenem, against different types of carbapenemases producing
by Enterobacteriaceae, belonging to Amber classe A, B, and
D. Those drugs associations were studied by the time-killing
kinetic curves as well as a new flow cytometry cell analysis.
We have recently developed a protocol for identification of
carbapenemases in 1 hour based on flow cytometry analysis (Silva
et al., 2016) with great accuracy. Additionally, a computational
protein–ligand docking analysis allowed us to understand the
molecular affinity of the different drugs regarding different
enzymes.
MATERIALS AND METHODS
Enterobacteriaceae Strains
Ten well characterized Enterobacteriaceae clinical strains were
selected; 4 KPC (two Klebsiella pneumoniae KPC-2, one
Escherichia coli KPC-3 and one K. pneumoniae KPC-3),
four verona integron-encoded beta-metalo-lactamases (one
Enterobacter cloacae VIM-1, one K. pneumoniae VIM-3, one
E. aerogenes VIM-4, and one K. penumoniae VIM-4) and two
OXA-like strains (K. pneumoniae OXA-48 and K. pneumoniae
OXA-181).
Chemicals
Ertapenem (Merck & Co.), doripenem (Ortho-McNeil-Janssen
Pharmaceuticals), meropenem (Fresenius Kabi Pharma
Portugal), imipenem (LKT Laboratories), and ceftazidime
(Sigma) were reconstituted with normal saline according to the
manufacturer’s instructions immediately before use; solutions
were kept refrigerated, protected from light, and discarded
after 8 h.
MIC Testing
Minimal inhibitory concentrations testing regarding the four
carbapenems and ceftazidime was determined according to
Clinical Laboratory Standard Institute microdilution reference
method (CLSI, 2014) using cation-adjusted Mueller-Hinton
broth. Pseudomonas aeruginosa ATCC 27853 was used as quality
control.
ESBL Detection
Extended-spectrum β-lactamases (ESBL) were detected by disk
diffusion agar test (both ceftazidime and cefotaxime without and
with clavulanic acid).
Time-Kill Assays
Time-kill assays were performed to compare the effect produced
by meropenem, imipenem, or doripenem either alone or with
ertapenem against a bacterial suspension. Approximately 1× 106
cells/mL was incubated with ertapenem (0.5 and 2 mg/L) in the
absence or in the presence of 8 mg/L of meropenem, doripenem,
or imipenem. Carbapenem concentrations represent usual levels
in human simulated regime of continuous infusion used in
critically ill patients (Abdul-Aziz et al., 2012). Ceftazidime at
100 mg/L was also incubated with ertapenem under the same
conditions (Georges et al., 2012). Non-treated bacterial cells were
used as controls. After 2, 4, 6, 8, and 24 h of incubation at 37◦C,
optical density was measured and the number of colony forming
units (CFUs) quantified. These procedures were repeated after
drug reinforcements each 2 h. Synergy was defined as a≥ 2 log10
decrease in CFUs/mL between the combination and ertapenem
alone; bactericidal effect was defined as a ≥ 3-log10 decrease
in CFUs/mL comparing the carbapenem combination with the
starting inoculum.
Flow Cytometric Assay
For flow cytometry analysis after 2 h incubation time (from time-
kill assays), 1 mL of the bacteria suspensions were stained with
0.5 µg/mL DiBAC4-(3) (Sigma), a membrane potential dye and
the intensity of fluorescence measured in a FACSCalibur (BD) at
FL1 (530/30nm). In the presence of depolarized cells, meaning
cell lesion, the intensity of fluorescence increases.
Computational Analysis
Computational analysis through protein–ligand docking
calculations (Sousa et al., 2006, 2013) was performed to
evaluate the relative binding affinity of carbapenems to different
carbapenemases. Initially, a thorough validation of the docking
conditions for different carbapenemases was performed, using 10
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known carbapenemase complexes taken from the PDB. Docking
conditions adjusted at this stage included the box size and
position, number of solutions, and the exhaustiveness parameter,
until the docking results were able to reproduce the known
X-ray poses with a maximum rmsd of 1 Å. The same docking
conditions were later used in docking ertapenem, doripenem,
meropenem, and imipenem against the structures of 13 different
carbapenemase enzymes from classes A (five enzymes), B (three
enzymes), and D (five enzymes) taken from the Protein Data
Bank (see details and results in Table 2). This procedure was
repeated with two different docking programs (Autodock Vina
and GOLD) (Jones et al., 1997; Trott and Olson, 2010) and
TABLE 1 | Acquired-carbapenemase-producing isolates tested.
MIC (mg/L)
Carbapenemase (no. of isolates) Species ERT IMP MEM DOR CAZ ESBL
KPC (4) K. pneumoniae 128–256 16–32 32–128 32–64 512 −
VIM (4) E. cloacae 64–256 32–64 64–128 64–128 >512 +
OXA (2) K. pneumoniae 4–8 4–8 4–8 4 16 +
ERT, ertapenem; IMP, imipenem; MEM, meropenem; DOR, doripenem; CAZ, ceftazidime.
FIGURE 1 | (A) Time-kill curves of various antibiotic combinations against a strain of Klebsiella pneumoniae KPC-2, a strain of Enterobacter cloacae VIM-4, and a
K. pneumoniae OXA-48. Each line represents ertapenem (ERT) either alone or associated with meropenem (MEM), imipinem (IMP), or doripenem (DOR) reinforced
with the respective drugs each 2 h. Ertapenem plus imipenem (∗) is shown as an example of the treatment without reinforcement. The association of ERT 2 mg/L
with ceftazidime (CAZ) 100 mg/L against KPC-2 producing bacteria is also represented. (B) Overlay of histograms obtained by flow cytometry. For each strain, cells
stained with DiBAC4(3) are represented after 2 h treatment with ERT 2 mg/L (a), ERT 0.5 mg/L plus IMP 8 mg/L (b), and ERT 2 mg/L plus IMP 8 mg/L (c).
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with five independent scoring functions (VINA, ChemPLP,
ASP, GoldScore, and ChemScore) to evaluate the corresponding
binding affinities. Average values of each scoring function for
each carbapenemase-carbapenem complex were calculated and
the statistical significance of the different predictions for each
carbapenem was determined through a two-tailed t-test.
RESULTS AND DISCUSSION
Phenotypic profiles of the strains used in the study are described
in Table 1. None of the carbapenems alone produced a significant
reduction of CFUs number or membrane depolarization,
compared to controls. Figure 1 shows time-kill curves and
flow cytometry results of typical examples of each type of
carbapenemase-producing bacteria. Whenever the cells were
incubated with ertapenem associated with other carbapenem, a
synergistic effect was evident soon after 2 h with meropenem,
doripenem, or imipenem on all KPC- and OXA-producing
strains and a bactericidal effect at 4 h (Figure 1A). In VIM-
producing strains this effect was observed only with imipenem
(Figure 1A). A sustained reduction of CFUs counts was observed
only if treatment was reinforced every 2 h (Figure 1A); effects
at 24 h were similar to 8 h effect. The association between
ertapenem and other carbapenem was bactericidal only on OXA-
producing strains (Figure 1A). A synergistic effect between
ertapenem and ceftazidime was also achieved in ESBL-negative
KPC strains (Figure 1A). No synergism was observed in ESBL
co-producers using that combination. The synergistic effect
was ertapenem dose-dependent (Figure 1B). Flow cytometric
analysis corroborated CFUs results, showing cell depolarization
after treatment with ertapenem associated with each different
carbapenem, for KPC and OXA enzymes, but only with
ertapenem/imipenem for VIM-4 enzyme (Figure 1B). Results
obtained with VIM-1 and VIM-3 were similar. Protein–ligand
docking calculations with the different scoring functions showed
that ertapenem had the highest affinity, whereas imipenem
had the lowest affinity toward carbapenemases (Table 2). This
tendency was observed with all the five independent scoring
functions used in this study and for all the 13 different
carbapenamase enzymes considered. For VINA, ChemScore,
and GoldScore the significance level of this difference was
over 90%.
There were no marked differences between the three
carbapenemase families tested. The computationally predicted
binding affinities between ertapenem and enzymes suggest
weak and reversible binding. A combination of ertapenem
with doripenem shows promising results regarding a KPC
K. pneumoniae strain both in vitro and in vivo (Bulik and
Nicolau, 2011). Wiskirchen et al. (2013a,b, 2014b) also showed
in a murine infection model a large variation of efficacy
of carbapenem monotherapy against bacteria producing KPC,
NDM-1, and OXA-48 enzymes. In immunocompetent mice
doripenem (2 g q8h) with ertapenem (1 g qd) increased the
efficacy over doripenem alone for the isolate with a doripenem
MIC of 8 µg/mL (Bulik and Nicolau, 2011). In our study,
imipenem with ertapenem showed synergy against all kinds of
carbapenemase-producing bacteria. Meropenem or doripenem
associated to ertapenem were not active against VIM. VIM
was the only MBL studied. Therefore extrapolation to other
subtypes (for instance, IMP) requires further studies despite
structural similitudes. The highest synergistic effect was observed
in OXA producing-strains in agreement with Wiskirchen et al.
(2014a) that describe a higher efficacy of dual carbapenem
regimes when MICs are low. A different approach was taking
by Poirel et al. (2016) and their data strongly support the
hypothesis that dual carbapenem combinations might be effective
against serine-b-lactamase producers (KPC, OXA-48). And the
imipenem-containing combinations appeared to be the most
efficient. Rationale of using ertapenem plus other carbapenems in
carbapenemase producing Enterobacteriaceae is similar to the use
of clavulanate with amoxicillin on TEM-1 producers. However, in
TABLE 2 | Results of the application of five independent scoring functions in the evaluation of the binding ability of the four carbapenems tested, against
13 X-ray structures of different carbapenemase enzymes from Classes A, B, and D.
Vinaa ChemPLPb ASPb GoldScoreb ChemScoreb
Class A (3BFC, 3RXW, 1BUL, 3NI9, 4MXH) Ertapenem −7.9 ± 0.4 71.0 ± 8.7 30.9 ± 5.1 60.6 ± 5.8 34.7 ± 3.5
Doripenem −7.7 ± 0.2 64.4 ± 10.8 27.6 ± 4.7 62.2 ± 5.3 32.5 ± 1.1
Meropenem −7.8 ± 0.4 64.3 ± 7.2 26.6 ± 3.2 56.9 ± 4.0 30.0 ± 1.6
Imipenem −6.7 ± 0.2 62.9 ± 4.7 21.2 ± 3.3 51.9 ± 9.1 27.6 ± 1.8
Class B (3WXC, 2YZ3, 4EYB) Ertapenem −7.7 ± 0.8 103.3 ± 12.7 46.7 ± 2.6 80.9 ± 6.9 46.5 ± 7.6
Doripenem −7.5 ± 0.6 109.0 ± 5.7 43.5 ± 1.9 75.9 ± 3.0 46.7 ± 5.0
Meropenem −7.5 ± 0.5 105.0 ± 6.8 43.0 ± 1.7 70.5 ± 5.4 44.3 ± 4.4
Imipenem −6.4 ± 0.5 98.6 ± 8.7 34.5 ± 2.4 76.8 ± 3.7 42.8 ± 3.1
Class D (3ISG, 4MLL, 4JF4, 3LCE, 3ZNT) Ertapenem −8.8 ± 0.9 76.0 ± 4.6 36.3 ± 4.5 78.2 ± 6.3 33.3 ± 3.3
Doripenem −7.6 ± 0.3 70.7 ± 5.0 33.4 ± 2.4 72.1 ± 4.1 31.0 ± 3.2
Meropenem −7.5 ± 0.5 68.5 ± 3.7 32.4 ± 3.3 70.0 ± 4.1 29.4 ± 3.8
Imipenem −6.5 ± 0.7 65.2 ± 6.0 27.4 ± 3.4 65.8 ± 5.7 26.7 ± 3.2
t-test (ertapenem vs imipenem)c 100.0% 55.1% 99.7% 92.7% 77.4%
PDB codes given in parenthesis. Highest affinity ligand for each scoring function indicated in bold. aThe Vina Scoring function reflects the predicted binding affinity in
kcal/mol (Trott and Olson, 2010). bThe ChemPLP, ASP (the Astex Statistical Potential), GoldScore, and ChemScore scoring functions are dimensionless, however, in each
case, the scale of the score gives a guide as to how good the pose is. The higher the score, the better the docking result is likely to be (Jones et al., 1997). cStatistical
significance of the average scoring values for ertapenem and imipenem being statistically different calculated from a two-tailed t-test.
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our case, clavulanate has no inhibitory effect on carbapenemases.
The only one in which this inhibitory effect is slightly present
is with KPC enzymes but this inhibition is far from clinical
use. In the future, this assay can be eventually compared with
ceftazidime/avibactam combination (only with KPC or OXA-
48-like enzymes) (Chahine et al., 2015). Flow cytometry is an
excellent tool, still unexplored in Microbiology, allowing to
study antimicrobial activity (Pina-Vaz et al., 2005; Pina-Vaz and
Rodrigues, 2010) drug associations (Teixeira-Santos et al., 2012),
and mechanisms of resistance (Faria-Ramos et al., 2013; Silva
et al., 2016). Flow cytometric results showed that even at a low
concentration and a short incubation time, a synergistic effect
could be easily observed and quantified.
CONCLUSION
We concluded that all carbapenemases easily hydrolyze
ertapenem allowing the other carbapenems to reach their
bacterial targets. These results turn important the characteriza-
tion of the carbapenemase present on the strain which is not
performed by all the clinical laboratories; the available methods
are cumbersome, expensive and gave late results. Easier and faster
laboratorial methods are need.
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